LivaNova (LIVN) AI Stock Analysis

• Market Cap: $3.46B
• Dividend Yield: N/A
• Average Volume (3M): 625.71K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.02
• Revenue Growth: 8.97%
• EPS Growth: -1024.86%
• Country: US
• Employees: 2,900
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 1.11
• Shares Outstanding: 54,605,526
• 10 Day Avg. Volume: 590,750
• 30 Day Avg. Volume: 625,707
• PEG Ratio: 0.16
• Price to Book (P/B): 1.90
• Price to Sales (P/S): 2.00
• P/FCF Ratio: 18.48
• Enterprise Value/Market Cap: 0.79
• Enterprise Value/Revenue: 2.02
• Enterprise Value/Gross Profit: 2.95
• Enterprise Value/Ebitda: -32.80
• 1Y Price Target: $65.83
• Price Target Upside: 5.04% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 6
• EPS Forecast (FY): 3.86
• Revenue Forecast (FY): $1.38B

• Rating: 63 Neutral
• Price Target: $67.00 ▲(6.91% Upside)

LivaNova's overall stock score is driven by strong technical momentum and positive earnings call highlights, including robust revenue growth and improved financial metrics. However, profitability concerns and valuation challenges, such as a negative P/E ratio, weigh on the score. The absence of a dividend yield further impacts valuation attractiveness.

Positive Factors

Revenue Growth

Strong revenue growth in key segments like cardiopulmonary and epilepsy indicates effective market strategies and product demand.

Strategic Roadmap

A clear strategic roadmap with ambitious growth targets suggests strong leadership and a focus on long-term value creation.

Cash Generation

Robust cash flow growth supports financial flexibility and potential reinvestment in innovation and expansion.

Negative Factors

Profitability Challenges

Persistent profitability issues highlight operational inefficiencies, potentially hindering long-term financial health.

Component Supply Challenges

Supply chain constraints can limit growth opportunities and affect the company's ability to meet market demand.

Currency and Tariff Impacts

Currency and tariff challenges can erode profitability, affecting the company's competitive position and pricing strategies.

LivaNova Business Overview & Revenue Model

Company Description

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products, such as cardiopulmonary and respiratory support solutions. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.

How the Company Makes Money

LivaNova generates revenue through the sale of its medical devices and therapies in the cardiovascular and neuromodulation sectors. Key revenue streams include the sale of heart valves, perfusion systems, and neuromodulation devices, which are often sold directly to hospitals and healthcare providers. The company also benefits from recurring revenue through the sale of consumables and accessories related to its devices. Additionally, LivaNova engages in strategic partnerships and collaborations with healthcare providers and research institutions, which can enhance its product offerings and expand market reach, further contributing to its earnings.

LivaNova Financial Statement Overview

Summary

LivaNova's financial performance shows mixed results. While there is positive revenue growth and strong free cash flow generation, profitability is a concern with negative net profit and EBIT margins. The balance sheet is moderately stable with manageable leverage, but inefficiencies are evident with a negative return on equity.

Income Statement

LivaNova's income statement shows a mixed performance. The TTM (Trailing-Twelve-Months) revenue growth rate is positive at 3.03%, indicating some growth momentum. However, the company is struggling with profitability, as evidenced by a negative net profit margin of -16.12% and a negative EBIT margin of -13.53%. The gross profit margin remains relatively strong at 68.49%, but the negative EBITDA margin of -6.39% highlights operational challenges.

Balance Sheet

The balance sheet reflects moderate stability. The debt-to-equity ratio has improved to 0.41 in the TTM, indicating a manageable level of leverage. However, the return on equity is negative at -17.66%, suggesting inefficiencies in generating returns for shareholders. The equity ratio stands at 45.25%, showing a reasonable level of equity financing.

Cash Flow

Cash flow analysis reveals some positive trends. The free cash flow growth rate is strong at 18.08% in the TTM, and the free cash flow to net income ratio is healthy at 0.76, indicating good cash generation relative to net income. However, the operating cash flow to net income ratio is relatively low at 0.30, suggesting potential issues in converting income into cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.35B	1.25B	1.15B	1.02B	1.04B	934.24M
Gross Profit	924.02M	870.87M	771.25M	707.23M	705.99M	594.76M
EBITDA	-83.20M	202.52M	38.48M	30.90M	-6.33M	6.35M
Net Income	-217.47M	63.23M	17.55M	-86.25M	-135.82M	-348.82M
Balance Sheet
Total Assets	2.56B	2.51B	2.43B	2.29B	2.20B	2.40B
Cash, Cash Equivalents and Short-Term Investments	646.08M	428.86M	266.50M	214.17M	207.99M	252.83M
Total Debt	486.55M	676.77M	640.40M	580.43M	286.70M	709.14M
Total Liabilities	1.40B	1.19B	1.15B	1.09B	906.31M	1.29B
Stockholders Equity	1.16B	1.32B	1.28B	1.21B	1.29B	1.11B
Cash Flow
Free Cash Flow	191.43M	135.93M	39.93M	43.40M	77.07M	-114.40M
Operating Cash Flow	250.65M	183.04M	74.91M	69.90M	102.54M	-79.40M
Investing Cash Flow	-53.36M	-48.16M	-40.33M	-38.40M	36.90M	-41.80M
Financing Cash Flow	-226.22M	18.55M	21.48M	280.10M	-181.48M	310.80M

LivaNova Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 62.67
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LIVN, the sentiment is Positive. The current price of 62.67 is above the 20-day moving average (MA) of 58.62, above the 50-day MA of 55.12, and above the 200-day MA of 47.42, indicating a bullish trend. The MACD of 2.74 indicates Negative momentum. The RSI at 65.41 is Neutral, neither overbought nor oversold. The STOCH value of 78.41 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for LIVN.

LivaNova Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
INSP	79 Outperform	$3.98B	93.83	6.54%	―	16.81%	34.90%
TMDX	78 Outperform	$4.67B	55.14	32.48%	―	41.20%	173.53%
UFPT	76 Outperform	$1.67B	25.01	18.31%	―	29.47%	23.24%
ITGR	67 Neutral	$2.45B	29.24	5.18%	―	7.81%	-26.32%
LIVN	63 Neutral	$3.46B	―	-17.63%	―	8.97%	-1024.86%
AORT	58 Neutral	$2.11B	―	-2.45%	―	9.81%	-1067.00%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

LivaNova Corporate Events

LivaNova PLC Reports Strong Q3 2025 Results

LivaNova PLC is a global medical technology company specializing in innovative solutions for neurological and cardiac conditions, operating in over 100 countries. In its third-quarter 2025 earnings report, LivaNova announced significant revenue growth and an increase in its full-year financial guidance. The company reported a 12.5% increase in revenue, reaching $357.8 million, and an adjusted diluted earnings per share of $1.11. The launch of the Essenz Perfusion System in China contributed to the strong performance in the Cardiopulmonary segment, which saw an 18% revenue increase. The Neuromodulation segment also showed growth with a 6.9% increase in revenue. LivaNova’s strategic focus on expanding its market presence and advancing its product offerings is evident in its improved financial outlook. The company raised its full-year 2025 revenue growth expectations and adjusted earnings per share guidance, reflecting confidence in its continued growth trajectory. LivaNova’s management remains optimistic about the company’s future, emphasizing its commitment to innovation and market leadership in addressing unmet medical needs.

LivaNova PLC Reports Strong Q3 Growth Amid Challenges

LivaNova’s recent earnings call painted a picture of robust growth and strategic challenges. The company reported strong organic revenue growth, particularly in the cardiopulmonary and epilepsy segments, alongside improved financial metrics. Despite facing hurdles such as component supply constraints and adverse currency impacts, LivaNova has raised its full-year guidance, signaling a positive outlook for the future.

LivaNova’s VNS Therapy Study: A Potential Game-Changer for Depression Treatment

Study Overview: LivaNova PLC is conducting a study titled A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression. The study aims to evaluate whether active Vagus Nerve Stimulation (VNS) Therapy is more effective than no stimulation in reducing depressive symptoms in patients with treatment-resistant depression over a 12-month period.

LivaNova’s VNS Therapy Study: A Potential Game-Changer for Treatment-Resistant Depression

Study Overview: LivaNova PLC is conducting a global, multi-center observational study titled ‘A Global PRospective, Multi-cEnter, ObServational Post-markeT Study tO Assess shoRt, Mid and Long-term Effectiveness and Efficiency of VNS Therapy® as Adjunctive Therapy in reaL-world patIents With diFficult to Treat dEpression.’ The study aims to evaluate the short, mid, and long-term outcomes of Vagus Nerve Stimulation (VNS) Therapy in patients with treatment-resistant depression, highlighting its significance in addressing this challenging condition.

LivaNova Appoints Donald Zurbay to Board of Directors

On September 3, 2025, LivaNova PLC appointed Donald Zurbay to its Board of Directors and as a member of the Audit and Compliance Committee, effective September 4, 2025. Mr. Zurbay brings extensive experience from his leadership roles at Patterson Companies and St. Jude Medical, enhancing LivaNova’s strategic direction and governance.

The most recent analyst rating on (LIVN) stock is a Buy with a $64.00 price target. To see the full list of analyst forecasts on LivaNova stock, see the LIVN Stock Forecast page.